Center Laboratories Inc (晟德大藥廠) yesterday said that it plans to “unblind” the data from the phase II clinical trial of its diabetes drug candidate CS02 in the second half of this year, after completing the “last patient’s last visit” late last month.
“Last patient’s last visit” is considered a milestone and the final step toward completion of a clinical trial.
The firm would collect and unblind the data to see if the experimental drug is safe and effective, general manager Robert Hsu (許瑞寶) told the Taipei Times by telephone.
The double-blind and placebo-controlled phase II clinical test randomized 185 patients into four groups that received a single dose of placebo or CS02 in dosages of 150mg, 300mg or 450mg, and then evaluated them over a 12-week period, Hsu said.
“We wanted to see which dosage would be optimal. As CS02 is developed to restore impaired beta-cells in pancreatic islets that synthesize and secrete insulin, we do not think higher doses would necessarily have a better effect,” Hsu said.
All of the enrolled patients were type 2 diabetes patients for whom the first-line treatment metformin proved ineffective, he said.
Center Laboratories aims to market CS02 as a second-line treatment for people with type 2 diabetes, Hsu said.
The company would see whether the enrolled patients’ glycosylated hemoglobin level, which reflects the average blood glucose level over the past three months, decreased after taking CS02 and check their beta-cell activity to determine whether the drug works, Hsu said.
“We would focus on the two gauges for the time being, given that global regulators have not set official gauges for the assessment of type 2 diabetes patients,” he said.
If approved for marketing, CS02 would be taken daily in the initial stage, but patients could gradually reduce the dosage and eventually stop taking the drug as their beta-cells would be restored, Hsu said.
After unblinding the data, the firm would apply to hold meetings with regulators in Taiwan and the US to review the results, and discuss the protocols for a phase III trial if the results are good, he added.
Center Laboratories would look for partners in the US and China to help conduct phase III trials there to alleviate its financial burden, but plans to conduct the final tests in Taiwan by itself, Hsu said.
The firm’s revenue dropped 14.81 percent to NT$307 million (US$10.27 million) in the first three months of this year, as the sales of some antiviral drugs fell due to fewer people catching the flu during the period, Hsu said, adding that Taiwanese paid more attention to their health amid the COVID-19 pandemic.
The demise of the coal industry left the US’ Appalachian region in tatters, with lost jobs, spoiled water and countless kilometers of abandoned underground mines. Now entrepreneurs are eyeing the rural region with ambitious visions to rebuild its economy by converting old mines into solar power systems and data centers that could help fuel the increasing power demands of the artificial intelligence (AI) boom. One such project is underway by a non-profit team calling itself Energy DELTA (Discovery, Education, Learning and Technology Accelerator) Lab, which is looking to develop energy sources on about 26,305 hectares of old coal land in
Taiwan’s exports soared 56 percent year-on-year to an all-time high of US$64.05 billion last month, propelled by surging global demand for artificial intelligence (AI), high-performance computing and cloud service infrastructure, the Ministry of Finance said yesterday. Department of Statistics Director-General Beatrice Tsai (蔡美娜) called the figure an unexpected upside surprise, citing a wave of technology orders from overseas customers alongside the usual year-end shopping season for technology products. Growth is likely to remain strong this month, she said, projecting a 40 percent to 45 percent expansion on an annual basis. The outperformance could prompt the Directorate-General of Budget, Accounting and
Netflix on Friday faced fierce criticism over its blockbuster deal to acquire Warner Bros Discovery. The streaming giant is already viewed as a pariah in some Hollywood circles, largely due to its reluctance to release content in theaters and its disruption of traditional industry practices. As Netflix emerged as the likely winning bidder for Warner Bros — the studio behind Casablanca, the Harry Potter movies and Friends — Hollywood’s elite launched an aggressive campaign against the acquisition. Titanic director James Cameron called the buyout a “disaster,” while a group of prominent producers are lobbying US Congress to oppose the deal,
Two Chinese chipmakers are attracting strong retail investor demand, buoyed by industry peer Moore Threads Technology Co’s (摩爾線程) stellar debut. The retail portion of MetaX Integrated Circuits (Shanghai) Co’s (上海沐曦) upcoming initial public offering (IPO) was 2,986 times oversubscribed on Friday, according to a filing. Meanwhile, Beijing Onmicro Electronics Co (北京昂瑞微), which makes radio frequency chips, was 2,899 times oversubscribed on Friday, its filing showed. The bids coincided with Moore Threads’ trading debut, which surged 425 percent on Friday after raising 8 billion yuan (US$1.13 billion) on bets that the company could emerge as a viable local competitor to Nvidia
RSS